司帕沙星_MSDS_用途_密度_司帕沙星CAS号【110871-86-8】

Sparfloxacin是氟喹诺酮类抗菌素。

[ 描述 ]:

Sparfloxacin是氟喹诺酮类抗菌素。

[ 相关类别 ]:

信号通路 >> 抗感染 >> 细菌

研究领域 >> 感染

[参考文献]

[1]. Nakamura, S., et al., In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother, 1989. 33(8): p. 1167-73.

[2]. Pan, X.S. and L.M. Fisher, Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother, 1997. 41(2): p. 471-4.

[相关活性小分子]

[ 密度 ]:
1.4±0.1 g/cm3

[ 沸点 ]:
640.4±55.0 °C at 760 mmHg

[ 熔点 ]:
265°C

[ 分子式 ]:
C₁₉H₂₂F₂N₄O₃

[ 分子量 ]:
392.400

[ 闪点 ]:
341.1±31.5 °C

[ 精确质量 ]:
392.165985

[ PSA ]:
100.59000

[ LogP ]:
1.20

[ 外观性状 ]:
淡黄色粉末

[ 蒸汽压 ]:
0.0±2.0 mmHg at 25°C

[ 折射率 ]:
1.627

[ 储存条件 ]:
Store at 0-5°C

CHEMICAL IDENTIFICATION

RTECS NUMBER :: VB1986500

CHEMICAL NAME :: 3-Quinolinecarboxylic acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5 -dimethyl-1- piperazinyl)-4-oxo-, cis-

CAS REGISTRY NUMBER :: 110871-86-8

LAST UPDATED :: 199709

DATA ITEMS CITED :: 15

MOLECULAR FORMULA :: C19-H22-F2-N4-O3

MOLECULAR WEIGHT :: 392.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4795751

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: >600 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 14,413,1989 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 22400 mg/kg/4W-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - urine volume decreased Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in leukocyte (WBC) count

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 39(Suppl 4),180,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72800 mg/kg/26W-I

TOXIC EFFECTS :: Liver - changes in liver weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1209,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 1260 mg/kg/4W-I

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects Gastrointestinal - nausea or vomiting Blood - other changes

REFERENCE :: NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 39(Suppl 4),195,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 4550 mg/kg/26W-I

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1225,1991 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3300 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1257,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 3300 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1257,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 7200 mg/kg

SEX/DURATION :: female 17-20 day(s) after conception lactating female 20 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1275,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 45500 mg/kg

SEX/DURATION :: male 91 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 19,1241,1991

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H315-H319-H335

[ 警示性声明 ]:
P261-P305 + P351 + P338

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Gloves

[ 危害码 (欧洲) ]:
Xi:Irritant;

[ 风险声明 (欧洲) ]:
R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
2

[ RTECS号 ]:
VB1986500

司帕沙星上游产品

司帕沙星下游产品

1. 2，3，4，5-四氟苯甲酸溶于1，2-二氯乙烷，在60℃滴加发烟硝酸和浓硫酸(1：1，体积比)的混合液，在70℃反应后放置过夜。将反应液倾入水中，静置分层。水层用二氯乙烷提取，提取液浓缩，残液用四氢呋喃重结晶，得硝化产物(I)，收率60%。
该硝化产物和氯化亚砜及数滴二甲基甲酰胺一起，回流至固体全溶。蒸出未反应的氯化亚砜，残液溶于甲苯，在-5-0℃下加到镁条和无水乙醇、四氯化碳、丙二酸二乙酯及甲苯的混合液中，反应后室温过夜。倾人冰水和浓盐酸的混合液，静置分层。水层用甲苯提取。提取液用饱和盐水洗，干燥，减压浓缩。往残液中加入水和浓硫酸，回流，冷却。用二氯甲烷提取，提取液用饱和盐水洗，干燥，浓缩得酯化产物(Ⅱ)，收率90%。
酯化产物(1I)、原甲酸三乙酯和醋酐，一起回流，减压浓缩得缩合产物 (Ⅲ)，收率95%。
将(Ⅲ)、乙醇和环丙胺，一起回流。回收乙醇，再加入二甲基甲酰胺和无水碳酸钠，90℃反应。冷却，过滤，得环合产物(Ⅳ)，收率71%。
铁粉、水和浓盐酸回流，冷至85℃滴加环合产物(Ⅳ)的乙醇溶液，回流。热滤，用乙醇洗铁泥。滤液和洗液合并，蒸出乙醇。冷却，过滤，乙醇重结晶，得还原产物(V)，收率74.8%。
还原产物(V)在6mol/L盐酸中回流，冷至室温用20%氢氧化钠调至中性。冷却，过滤，水洗，用乙醇重结晶，得水解产物(Ⅵ)，收率95%。
水解产物(Ⅵ)、醋酐和醋酸混合，加数滴浓硫酸，回流。减压浓缩后水洗，用氯仿重结晶，得酰化产物(Ⅶ)，收率90%。酰化产物(Ⅶ)、顺2，6-二甲基哌嗪和吡啶，一起回流。浓缩至干后水洗，乙醇重结晶，得缩合产物(Ⅷ)，收率84%。
缩合产物(Ⅷ)和5%氢氧化钠于110℃下反应。用水稀释，稀盐酸调至Ph=9。过滤，用氨水重结晶，得司氟沙星，收率91％，熔点267～270℃(分解)。

2. 2，3，4，5-四氟-6-硝基苯甲酸的制备

在反应瓶中加入2，3，4，5-四氟苯甲酸50g（0.258mol）和二氯乙烷200ml，搅拌加热至60 ºC，滴加发烟硝酸50ml与浓H2SO450ml混合液，加毕，于70 ºC搅拌反应5.5h（TLC跟踪）。放置过夜。将反应混合物倒入冰水中，静置分层，水层用1，2-二氯乙烷（20ml×3）提取，合并有机层，减压蒸除二氯乙烷（回收），剩余物用THF重结晶得淡黄色粉末2，3，4，5-四氟-6-硝基苯甲酸37.0g，收率60%，mp135~136 ºC。

3. 2，3，4，5-四氟-6-硝基苯甲酰乙酸乙酯的制备

在反应瓶中加入2，3，4，5-四氟-6-硝基苯甲酸64.2g（0.27mol）、氯化亚砜29ml（0.4mol），搅拌，加入5滴DMF，加热回流直至固体全部溶解，蒸馏回收未反应的氯化亚砜，剩余物为68.6g，收率98.7%。

在干燥的反应瓶中加入无水乙醇25ml、四氯化碳2ml和干燥镁条6.8g（0.28mol），搅拌，当反应开始时加入丙二酸二乙酯43.2g（0.27mol）与无水乙醇25ml、甲苯100ml的混合液，然后在50~60 ºC反应直至完全，将反应液冷至-5~0 ºC。加入剩余物与甲苯20ml的混合液。加毕，在-5~0 ºC搅拌1h。置于室温过夜。将反应液倒入冰水100ml及浓盐酸10ml混合液中，静置分层。水层用甲苯（40ml×2）提取，合并甲苯层，饱和食盐水洗，无水Na2SO4干燥，过滤，滤液减压回收甲苯#得二酯化合物。向其中加水100ml及浓H2SO40.2ml，搅拌回流5h。冷却。用二氯甲烷（3ml×3），提取，合并提取液，饱和食盐水洗，无水Na2SO4干燥，过滤，滤液蒸除二氯甲烷，得黑色油状物2，3，4，5-四氟-6-硝基苯甲酰乙酸乙酯74.0g，收率90%，直接用于下步反应，不需进一步纯化。

4. a-（2，3，4，5-四氟-6-硝基苯甲酰）-β-乙氧基丙烯酸乙酯的制备

将2，3，4，5-四氟-6-硝基苯甲酰乙酸乙酯35g（0.113mol）、原甲酸三乙酯29ml（0.174mol）和乙酸酐250ml加到反应瓶中，搅拌回流3h。减压浓缩得a-（2，3，4，5-四氟-6-硝基苯甲酰）-β-乙氧基丙烯酸乙酯39.2g，收率95.0%。

5. 1-环丙基-6，7，8-环丙基-三氟-1，4-二氢-5-硝基-4-氧代喹啉-3-羧酸乙酯的制备

在反应瓶中加入39.0g（0.107mol）、乙醇100ml、环丙胺6.2g（0.109mol），搅拌回流（TLC跟踪），3h反应完毕，蒸除乙醇，得剩余物，不经纯化，直接向其中加入DMF200ml、无水Na2CO328.4g（0.268mol）于90 ºC搅拌反应3h（用TLC跟踪，一般3h反应毕），冷却，过滤，得27.1g，收率71%，mp263~265 ºC。

6. 5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸乙酯

在反应瓶中加入水200ml、铁粉86.1g（1.54mol），搅拌下滴加浓盐酸15ml，加热回流15min，冷至85 ºC，滴加1-环丙基-6，7，8-环丙基-三氟-1，4-二氢-5-硝基-4-氧代喹啉-3-羧酸乙酯的乙醇溶液【21.9g（61.5mmol）1-环丙基-6，7，8-环丙基-三氟-1，4-二氢-5-硝基-4-氧代喹啉-3-羧酸乙酯溶于500ml乙醇】，搅拌回流6h（TLC跟踪）。热过滤，铁泥用乙醇（20ml×3）洗。合并洗液和滤液，浓缩回收乙醇，冷却#过滤，固体

用乙醇重结晶，得5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸乙酯15.0g，收率74.8%，mp218.5~220.5 ºC。

7. 5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸的制备

在反应瓶中加入5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸乙酯19.7g（60.4mol）和6mol/L盐酸100ml，搅拌回流2h（TLC跟踪）。冷至温，用20%NaOH溶液调至pH中性，冷却，过滤，滤饼用水洗，乙醇重结晶得5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸17.1g，收率95%，mp274.5~276 ºC。

8. 5-乙酰氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸的制备

在反应瓶中加入5-氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸10g（33.6mmol）、乙酸酐20g（196mmol）、乙酸200ml，加5滴浓H2SO4，搅拌下回流1.5h（TLC跟踪）。减压浓缩，剩余物用水洗，氯仿重结晶，得5-乙酰氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸10.3g，收率90.0%，mp247~248 ºC（文献【12】报道mp247~248 ºC）。

9. 5-乙酰氨基-1-环丙基-6，8-二氟-1，4-二氢-7-（顺-3，5-二甲基-1-哌嗪基）-4-氧代喹啉-3-羧酸的制备

在反应瓶中加入5-乙酰氨基-1-环丙基-6，7，8-三氟-1，4-二氢-4-氧代喹啉-3-羧酸3.0g（8.82mmol）、顺-2，6-二甲基哌嗪1.3g（11.4mmol）和吡啶20ml，搅拌回流2h（TLC跟踪）。浓缩至干，剩余物用水洗，乙醇重结晶，得5-乙酰氨基-1-环丙基-6，8-二氟-1，4-二氢-7-（顺-3，5-二甲基-1-哌嗪基）-4-氧代喹啉-3-羧酸3.3g，收率84%，mp262~265 ºC（分解）。【文献【12】报道mp262~266ºC（分解）】。

10. 司氟沙星的合成

在反应瓶中加入5-乙酰氨基-1-环丙基-6，8-二氟-1，4-二氢-7-（顺-3，5-二甲基-1-哌嗪基）-4-氧代喹啉-3-羧酸1.8g（4.14mmol）和5%NaOH溶液10ml，于110 ºC搅拌反应1h。用水稀释，用稀盐酸调至Ph9，过滤，用氨水重结晶，得司氟沙星1.5g，收率91%，mp267~270 ºC（分解）【文献【12】报道mp266~269 ºC（分解）】。

New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.

Antimicrob. Agents Chemother. 51 , 3354-60, (2007)

Plasmid-mediated Qnr and AAC(6')-Ib-cr have been recognized as new molecular mechanisms affecting fluoroquinolone (FQ) resistance. C316, an Escherichia coli strain demonstrating resistance to various ...

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...

Interactions of a non-fluorescent fluoroquinolone with biological membrane models: A multi-technique approach.

Int. J. Pharm. 495 , 761-70, (2015)

Fluoroquinolones are antibiotics which act by penetrating into bacterial cells and inhibiting enzymes related to DNA replication, and metal complexes of these drugs have recently been investigated as ...

更多文献

公司名：上海化源世纪贸易有限公司

区域：上海市普陀区

价格：

联系人：徐经理

产品详情：司帕沙星

公司名：上海源溪生物科技有限公司

区域：上海市浦东新区

价格：
￥需询单/1g

联系人：赖经理

产品详情：CI 978

公司名：上海脉铂医药科技有限公司

区域：上海市嘉定区

价格：
￥329.0/50mg ￥需询单/1g ￥需询单/1g ￥需询单/1g

联系人：李先生

产品详情：Sparfloxacin

公司名：上海创赛科技有限公司

区域：上海市嘉定区

价格：
￥333.2/50mg

联系人：夏言

产品详情：Sparfloxacin

公司名：上海阿拉丁生化科技股份有限公司

区域：上海市浦东新区

价格：
￥61.9/1g ￥206.9/5g ￥418.9/1ml ￥2645.9/100g

联系人：阿拉丁

产品详情：Sparfloxacin

查看所有供应商请点击：

司帕沙星供应商

司帕沙星

司帕沙星用途

司帕沙星名称

司帕沙星生物活性

司帕沙星物理化学性质